Ovarian Cancer Clinical Trial

A Study of Opportunistic Salpingectomy to Prevent Ovarian Cancer

Summary

The purpose of this study is to find out how many participants are interested in a surgical preventive procedure after watching an educational video. Before and after watching the video, participants will complete questionnaires in the clinic.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Part I

Age ≥45 years
Scheduled visit with a nongynecologic surgeon
Female or assigned female at birth

Part II

Age ≥45 years
At least one in situ fallopian tube
No desire or plan to have children in the future

Average risk of developing ovarian cancer

° Note: Average risk patients are defined as patients with no known genetic risk factor for developing ovarian cancer. Patients who, after obtaining family history, are suspected to have a hereditary ovarian cancer syndrome but have not yet been tested, will be referred for genetic evaluation.

Planned nongynecologic, intraabdominal, or pelvic surgery
Deemed to be a suitable candidate by gynecologic surgeon and primary nongynecologic surgeon (for example, on the basis of surgical history and current malignancy status)
Approved and signed informed consent

Exclusion Criteria:

Part I

Not fluent in English

° If there is a non-english speaking participant who is a strong candidate and meets all other criteria for Part 2, they are able to go directly onto Part 2 without completing Part 1. (Please see additional details in section 4.1 and 7.0.)

Known inherited ovarian cancer susceptibility

Part II

Personal history of a gynecologic malignancy
Carrier of a hereditary breast or ovarian cancer variant (e.g., BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, MLH1, MSH2, MSH6, PMS2)
Suspicious ovarian, fallopian tube, or uterine lesion on preoperative imaging
Previous bilateral salpingectomy or bilateral salpingo-oophorectomy
Current pregnancy
Emergent procedure or emergency procedure that has to be completed within 24 hours where clinical consent occurs in the inpatient setting or where the patient's immediate well-being is in danger or condition may be life threatening
Primary surgeon anticipates that OS will add significant time (>30-40min) to the planned procedure.
Inability to access the pelvis (ex., patient prone/lateral position) during the planned procedure.
Known history of pelvic fibrosis or significant adhesions.
Procedures with palliative intent only

Study is for people with:

Ovarian Cancer

Estimated Enrollment:

400

Study ID:

NCT06312124

Recruitment Status:

Recruiting

Sponsor:

Memorial Sloan Kettering Cancer Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 10 Locations for this study

See Locations Near You

Johns Hopkins University (Data Collection Only)
Baltimore Maryland, 21287, United States More Info
Rebecca Stone, MD
Contact
410-955-8240
Dana Farber Cancer Institute (Data Collection Only)
Boston Massachusetts, 02115, United States More Info
Michelle Davis, MD
Contact
617-732-8840
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge New Jersey, 07920, United States More Info
Kara Long Roche, MD
Contact
646-608-3787
Memorial Sloan Kettering Monmouth (Limited protocol activities)
Middletown New Jersey, 07748, United States More Info
Kara Long Roche, MD
Contact
646-608-3787
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale New Jersey, 07645, United States More Info
Kara Long Roche, MD
Contact
646-608-3787
Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Limited protocol activities)
Commack New York, 11725, United States More Info
Kara Long Roche, MD
Contact
646-608-3787
Memorial Sloan Kettering Westchester (Limited Protocol Activities)
Harrison New York, 10604, United States More Info
Kara Long Roche, MD
Contact
646-608-3787
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York New York, 10065, United States More Info
Kara Long Roche, MD
Contact
646-608-3787
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Uniondale New York, 11553, United States More Info
Kara Long Roche, MD
Contact
646-608-3787
MD Anderson Cancer Center (Data Collection Only)
Houston Texas, 77030, United States More Info
Karen Lu, MD
Contact
713-745-8902

How clear is this clinincal trial information?

Study is for people with:

Ovarian Cancer

Estimated Enrollment:

400

Study ID:

NCT06312124

Recruitment Status:

Recruiting

Sponsor:


Memorial Sloan Kettering Cancer Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.